In this study, a simple and green strategy was reported to prepare bimetallic nanoparticles (NPs) by the combination of zinc oxide (ZnO) and copper oxide (CuO) using Sambucus nigra L. extract. The physicochemical properties of these NPs such as crystal structure, size, and morphology were studied by X-ray diffraction (XRD), field emission gun scanning electron microscopy (FEG-SEM), and transmission electron microscopy (TEM). The results suggested that these NPs contained polygonal ZnO NPs with hexagonal phase and spherical CuO NPs with monoclinic phase. The anticancer activity of the prepared bimetallic NPs was evaluated against lung and human melanoma cell lines based on MTT assay. As a result, the bimetallic ZnO/CuO NPs exhibited high toxicity on melanoma cancer cells while their toxicity on lung cancer cells was low.

Cancer is the main cause of morbidity and mortality worldwide, excluding infectious disease. Because of their lack of specificity in chemotherapy agents are used for cancer treatment, these agents have severe systemic side effects, and gradually lose their therapeutic effects because most cancers become multidrug resistant. Platinum nanoparticles (PtNPs) are relatively new agents that are being tested in cancer therapy. This review covers the various methods for the preparation and physicochemical characterization of PtNPs. PtNPs have been shown to possess some intrinsic anticancer activity, probably due to their antioxidant action, which slows tumor growth. Targeting ligands can be attached to functionalized metal PtNPs to improve their tumor targeting ability. PtNPs-based therapeutic systems can enable the controlled release of drugs, to improve the efficiency and reduce the side effects of cancer therapy. Pt-based materials play a key role in clinical research. Thus, the diagnostic and medical industries are exploring the possibility of using PtNPs as a next-generation anticancer therapeutic agent. Although, biologically prepared nanomaterials exhibit high efficacy with low concentrations, several factors still need to be considered for clinical use of PtNPs such as the source of raw materials, stability, solubility, the method of production, biodistribution, accumulation, controlled release, cell-specific targeting, and toxicological issues to human beings. The development of PtNPs as an anticancer agent is one of the most valuable approaches for cancer treatment. The future of PtNPs in biomedical applications holds great promise, especially in the area of disease diagnosis, early detection, cellular and deep tissue imaging, drug/gene delivery, as well as multifunctional therapeutics.

No abstract

edward syndrome screening in women 35-25 years old with polycystic ovary syndrome. Methodology: The statistical population is pregnant women in ardabil & sampling method is by census women who referred to a gynecologist. A sample of 100 35-25 year-old pregnant women, 50 pregnant women with no problems and 50 pregnant women with polycystic ovary syndrome were considered. The questionnaire contains information such as age, previous history of trisomy in the family and children, taking folic acid, marriage, parenthood, gestational age, history of smoking or alcohol, or take any other medicines, and was completed using interviews and extraction of office patient records. The results of the experiment answers were analyzed and and for data analysis using kolmogorov-smirnov test for normalization of the distribution of data and using pearson correlation test fir evaluate study  hypotheses , the t test and statistical software , spss22,  used in significance level of  05/0≥p .  Results: The results show that average serum papp-a levels in mothers aged 35-25 with polycystic ovary syndrome under treatment in comparison with serum papp-a levels in the 35-25 year-old women with polycystic ovary syndrome and other mothers had a low level. The results show that average free β-hcg levels in mothers aged 35-25 with polycystic ovary syndrome under treatment in comparison with free β-hcg levels in the 35-25 year-old women with polycystic ovary syndrome and other mothers had a low level. The results show that average crl  of mothers with polycystic ovary syndrome in comparison with crl of unaffected mothers for having a  fetus with edwards syndrome has high level. Conclusion: The results show that none of the test used in this study has no chance for fetus affect by edward syndrome.